bicuculline

Bicuculline is an alkaloid extracted from Corydalis decumbens, acting as a competitive antagonist of the neurotransmitter GABAA receptor (IC50 = 2 μM). It also blocks Ca2+-activated potassium (SK) channels and inhibits slow afterhyperpolarization (slow AHP). Bicuculline has anticonvulsant effects and is commonly used to establish mouse seizure models.

(-)-Bicuculline methobromide is a potent antagonist of GABAA receptor .

(-)-Bicuculline methochloride is a potent antagonist of GABAA receptor.

Bicuculline methobromide is a selective GABAA receptor antagonist with an IC50 of 3 μM. It can induce clonic-tonic seizures in mammals and block Ca²⁺-activated potassium channels, commonly used to establish models of epilepsy and related neurological disorders.

(+)-Bicuculline methiodide is a γ-aminobutyric acid type A (GABAA) receptor blocker that crosses the rat blood-brain barrier (BBB) and blocks epileptogens, which can be used to study neurological disorders such as epilepsy. (+)-Bicuculline methiodide reduces liver injury in septic rats.

Bicuculline methochloride is a competitive GABAA receptor antagonist and allosteric inhibitor with an IC50 of 1.7 μM. It blocks Ca²⁺-dependent activation of potassium channels, exhibits convulsant activity, and is suitable for epilepsy research.

Bicuculline (Standard) is a reference standard for research and analysis in studies involving Bicuculline. Bicuculline is an alkaloid extracted from Corydalis decumbens, acting as a competitive antagonist of the neurotransmitter GABAA receptor (IC50 = 2 μM). It also blocks Ca2+-activated potassium (SK) channels and inhibits slow afterhyperpolarization (slow AHP). Bicuculline has anticonvulsant effects and is commonly used to establish mouse seizure models.

GGTI 2147 FA, a selective GGT inhibitor, abolishes bicuculline-induced increase in dendritic spine density in hippocampal experiments and may reduce learning and memory abilities in mice.